Skip to content
MedsAcross

Medicine

Xifaxan 550 mg tablet

Rifaximin · Oral · Salix Pharmaceuticals
Available on requestPrescription onlyUS FDA

Xifaxan 550 mg tablet is a prescription medicine containing Rifaximin for oral use, marketed by Salix Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Ambient

Store XIFAXAN Tablets at 20° to 25°C (68° to 77°F), excursions permitted to…

Key facts

Active ingredient (INN)
Rifaximin
Brand
Xifaxan
Strength
550 mg
Dosage form
Tablet
Route
Oral
Packs
3 cartons, 60 tablets, 6 blister pack and 2 more
Marketing authorisation holder
Salix Pharmaceuticals
Manufacturers
Salix PharmaceuticalsCardinal Health
Origin register
US FDA, United States
Storage
Store XIFAXAN Tablets at 20° to 25°C (68° to 77°F), excursions permitted to 15° to 30°C (59° to 86°F).
Cold chain
Not required on record
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
ATC code
A07AA11 Rifaximin
HS code (indicative)
3004.20Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
1 May 2010
Identifiers
RxCUI 429662, 539789, 856664 +1DailyMed set ID c5e8e2fd-7087-4b78-9181-cc259c0be2f1, 7afafa63-3236-4212-9589-045db6b01c0bNDC 65649-303, 55154-6777Application NDA021361

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

PackCodeLabelerMarketed since
3 carton in 1 tray / 1 blister pack in 1 carton / 2 tablet in 1 blister pack65649-303-01Salix Pharmaceuticals1 May 2010
60 tablet in 1 bottle65649-303-02Salix Pharmaceuticals1 May 2010
6 blister pack in 1 carton / 10 tablet in 1 blister pack65649-303-03Salix Pharmaceuticals1 May 2010
3 carton in 1 tray / 1 blister pack in 1 carton / 3 tablet in 1 blister pack65649-303-05Salix Pharmaceuticals1 May 2010
360 tablet in 1 bottle, plastic55154-6777-8Cardinal Health1 May 2010

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
US FDAFirst approved 25 May 2004Drugs@FDA
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Other strengths and forms of Rifaximin

Clinical summary

Rifaximin is a rifamycin antibacterial indicated for treatment of travelers’ diarrhea (TD) caused by noninvasive strains of Escherichia coli in adult and pediatric patients 12 years of age and older, among other approved uses. MedsAcross supplies Rifaximin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Rifaximin

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Xifaxan 550 mg tablet for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.